tirzepatide weight loss trial results after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 Tirzepatide outperformed semaglutide weight-loss drug
Description
The magnitude of body weight and waist circumference reductions were similar for adults receiving the same tirzepatide dose, regardless of duration of disease
There are no hidden-fees and insurance is not required
The protocol was approved by local institutional review boards and the trial complied with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki
Eur J Intern Med [DOI] [PubMed] Taktaz F et al (2024) Evidence that Tirzepatide protects against diabetes-related cardiac damages
R., Buddingh, E
